Food and Drug Administration
Pulmonary-Allergy Drugs Advisory Committee
Briefing Information
Chiron
Corporation
NDA 50-799, Pulminiq™ (cyclosporine),
inhalation solution, Chiron, proposed for the increase in survival and for the
prevention of chronic rejection in patients receiving allogenic lung
transplants, in combination with standard immunosuppressive therapy.
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Chiron Corporation Pulminiq™
(cyclosporine) Briefing Material 
FDA
Disclaimer
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. §552). These redacted portions will appear as white space on the screen or on the printed page.